Nano-curcumin for the Treatment and Management of Diabetes Mellitus

Diabetes mellitus (DM) is a growing global health concern, placing increasing strain on healthcare systems. Curcumin, the primary bioactive compound in Curcuma longa (turmeric), has been reported to exhibit several therapeutic effects, including potential benefits for managing DM. However, its clinical use is limited by poor bioavailability. Nanotechnology, particularly nano-curcumin (nCUR), offers a promising solution by enhancing curcumin's delivery and effectiveness. Preclinical and clinical studies suggest that nCUR may help manage DM and its complications by reducing oxidative stress, genotoxicity, and mitochondrial dysfunction. Despite these promising results, the exact molecular mechanisms of nCUR remain unclear, and clinical evidence is still limited. Furthermore, there is a lack of global guidelines regulating the use of nanomaterials in medicine. In summary, while nCUR shows strong potential as a therapeutic option for diabetes, further research is necessary to elucidate its mechanisms, confirm its clinical efficacy and safety, and establish standardized guidelines for its use in healthcare.